Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

NDAQ:TMDX) The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into TransMedics Group, Inc. For Securities Fraud ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

TransMedics’ stock price has dropped $9.84, or 13%, since Scorpion released a report, titled “Walk Like An Egyptian,” leveling serious allegations against the company, including fraud ...

TransMedics has had a tough stretch of late. Last Friday, short-seller Scorpion Capital published a short report on the company. Management vehemently denied wrongdoing, and said it was exploring ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.